Healthcare of Ontario Pension Plan Trust Fund boosted its holdings in Amedisys, Inc. (NASDAQ:AMED - Free Report) by 2,159.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 27,200 shares of the health services provider's stock after acquiring an additional 25,996 shares during the period. Healthcare of Ontario Pension Plan Trust Fund owned 0.08% of Amedisys worth $2,497,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the business. Banque Cantonale Vaudoise purchased a new stake in Amedisys in the first quarter valued at approximately $60,000. Innealta Capital LLC purchased a new stake in shares of Amedisys in the 2nd quarter valued at $64,000. Covestor Ltd lifted its stake in Amedisys by 134.2% during the 1st quarter. Covestor Ltd now owns 780 shares of the health services provider's stock worth $72,000 after acquiring an additional 447 shares in the last quarter. Signaturefd LLC boosted its holdings in Amedisys by 88.2% during the 2nd quarter. Signaturefd LLC now owns 1,131 shares of the health services provider's stock valued at $104,000 after acquiring an additional 530 shares during the period. Finally, GAM Holding AG acquired a new position in Amedisys in the 2nd quarter valued at about $275,000. 94.36% of the stock is currently owned by institutional investors and hedge funds.
Amedisys Stock Down 0.3 %
NASDAQ AMED traded down $0.30 during trading hours on Monday, hitting $95.82. 443,440 shares of the company were exchanged, compared to its average volume of 334,731. The company has a quick ratio of 1.16, a current ratio of 1.16 and a debt-to-equity ratio of 0.30. The company has a 50 day moving average of $97.45 and a two-hundred day moving average of $95.09. The firm has a market cap of $3.13 billion, a price-to-earnings ratio of -149.72, a PEG ratio of 1.90 and a beta of 0.78. Amedisys, Inc. has a 52-week low of $89.55 and a 52-week high of $98.95.
Amedisys (NASDAQ:AMED - Get Free Report) last issued its earnings results on Wednesday, July 24th. The health services provider reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.22 by $0.10. The firm had revenue of $591.19 million during the quarter, compared to the consensus estimate of $579.34 million. Amedisys had a net margin of 4.02% and a return on equity of 12.39%. Equities research analysts anticipate that Amedisys, Inc. will post 4.66 earnings per share for the current year.
Analyst Ratings Changes
AMED has been the topic of a number of recent research reports. Cantor Fitzgerald reiterated a "neutral" rating and set a $101.00 price target on shares of Amedisys in a research note on Thursday, July 25th. William Blair cut Amedisys from an "outperform" rating to a "market perform" rating in a research note on Monday, July 1st. Finally, Deutsche Bank Aktiengesellschaft downgraded Amedisys from a "buy" rating to a "hold" rating and set a $101.00 price target on the stock. in a report on Monday, July 29th. Four equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $100.67.
View Our Latest Analysis on Amedisys
About Amedisys
(
Free Report)
Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.
Featured Stories
Before you consider Amedisys, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Amedisys wasn't on the list.
While Amedisys currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.